Biopharma, US FTC Portray Opposing Sides In Debate Over Patent ‘March-In’ Policy

 
• By Brenda Sandburg
  
Marching band
The Biden Administration proposal to expand the approach to exercising patent march-in rights has drawn thousands of comments. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Pink Sheet